Teva Pharmaceutical Industries Limited (TLV: TEVA)
Israel
· Delayed Price · Currency is ILS · Price in ILA| Market Cap | 77.42B |
| Revenue (ttm) | 61.33B |
| Net Income (ttm) | -1.71B |
| Shares Out | n/a |
| EPS (ttm) | -1.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 586,085 |
| Open | 6,720.00 |
| Previous Close | 6,579.00 |
| Day's Range | 6,701.00 - 6,782.00 |
| 52-Week Range | 3,250.00 - 7,057.00 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 1, 2024 |
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. ... [Read more]
Financial Performance
In 2023, TEVA's revenue was $15.85 billion, an increase of 6.17% compared to the previous year's $14.93 billion. Losses were -$559.00 million, -77.15% less than in 2022.
Financial numbers in USD Financial StatementsNews
Teva to Present at the Bank of America 2024 Global Healthcare Conference
TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Bank ...
Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial
Baltimore said on Tuesday that it has settled with Walgreens over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 ...
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
The City of Baltimore, led by Mayor Brandon M. Scott , reached an $80 million settlement with Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) to resolve claims against the company for its role in th...
Teva facing EU fine for disparaging Copaxone rival: report
Exclusive: Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say
Teva , the world's largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, people ...
Cheap Teva Stock Should Reward Patient Investors
Teva is poised to benefit from rising demand for generic drugs due to a favorable macro and political environment. The company's valuation is attractive despite its high debt load, which it is likely ...
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan notes that while there's a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be d...
CareRx names Suzanne Brand as finance chief
CareRx announced Suzanne Brand as their new CFO, previously with Teva Pharmaceuticals.
Medincell's Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI)
MONTPELLIER, France--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced during the 22nd Annual Global Healthcare Conference...
Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Morgan Stanley 22nd Annual Global Healthcare Conference Call September 4, 2024 11:30 AM ETCompany...
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan...
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
The recent move by the U.S. government to negotiate Medicare drug prices has triggered speculation about which drugs could be targeted in the next round of negotiations, which is set for 2027. Last we...
Teva Pharmaceutical hits a new 52-week high
Teva Pharmaceutical hits a new 52-week high
Teva's Transformation: From Generics Leader To Branded Drug Innovator
Teva's revenue and profit were driven by significant progress in developing its generics business, despite increased competition. Read more on TEVA stock here.
Teva's Transformation: From Generics Leader To Branded Drug Innovator
Teva's revenue and profit were driven by significant progress in developing its generics business, despite increased competition. Read more on TEVA stock here.
$100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 7.47% on an annualized basis producing an average annual return of 20.62%. Currently, Teva Pharmaceutical I...
Teva Pharmaceutical Industries Limited (TEVA) Q2 2024 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q2 2024 Earnings Call Transcript
Medincell's partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): Olanzapine LAI (mdc-TJK) No PDSS* observed after completion of c.95% of the targeted injections for submission Full phase 3 safety result...
Watch CNBC's full interview with Teva Pharma CEO Richard Francis
Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss how much of the company's momentum is around its generic obesity drug, outlooks on the company's earnings, and much more.
Teva Pharma CEO: Majority of momentum came from innovative business, not GLP-1s
Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss how much of the company's momentum is around its generic obesity drug, the market's excitement around its GLP-1 drug, and much more.
Teva Pharmaceutical Industries (TEVA) Q2 2024 Earnings Call Transcript
TEVA earnings call for the period ending June 30, 2024.
Teva Pharma CEO: Majority of momentum came from innovative business, not GLP-1s
Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss how much of the company's momentum is around its generic obesity drug, the market's excitement around its GLP-1 drug, and much more.
Teva Beats Q2 Estimates, Raises Annual Outlook On Strong Generic, Austedo Sales
On Wednesday, Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported second-quarter 2024 sales of $4.16 billion, beating the consensus of $4.06 billion . Revenues increased 7% year-over-year and 11...